Neo7logix PES (Personalized Edited Sequence) is registered as a provisional patent with the USPTO as an integral part of PBIMA (Precision-Based Immunomolecular Augmentation). Neo7logix’s unification API is also known as NEO7UAPI.
Neo7Logix’s precision profiling platform to select final pooled sequence immune editing design of the patient matching sequences specific to the patient’s disease but more importantly, unique to that patients’ immune defense and regulatory requirements. The focal strength of PES is the activation of natural cell and humoral defense and regulation using the patient’s prime edited sequences to initiate sustained immunity against disease.
Neo7logix proprietary architecture (NEO7UAPI) is applicable for cancer, autoimmune, chronic viral infection and neurodegenerative diseases. Neo7logix’s precision can also predict “best fit” target drug design and safe use of natural-based USP agents for many disease types.
Precision-Based Immuno-Molecular Augmentation (PBIMA) with its Personalized Edited Sequence (PES) is an approach to simultaneously activate and/or suppress the patients immune system as needed in a highly precise manner focusing it against a precision ranked limited number of specific antigens and molecular pathways identified as the disease cause and architects prime edited sequences to initiate immune mediated defense and regulation for sustained immunity.
PBIMA-PES is a gene /protein /cell communication network-editing interface that finds and augments in repairing detected faults that globally effect an individual’s evolutionary regenerative adaptation and favors disease free survival. The focal design emphasis is upon the individual patient’s specific immune editing requirements to defend against the disease rather than just on the general disease diagnosis. Therefore, this individualization can only be used specifically for the individual patient and not commercialized for the general population. This is a unique niche not in existence in the current conventional medical treatment environment.
Neo7Logix, offers this high affinity profiling, matching, selection based upon the patient’s own immune compatibility, immunoediting ability, and adaptation process in addition to treatment in the fight against disease. We are offering this platform technology to the market to collectively fight disease, save lives and give quality of life and longevity. This is a comprehensive solution from A to Z that will significantly lower existing burdensome health disparities.
The Figure below illustrates the process flow from patient sample through patient treatment: